Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

Zhejiang Doer Biologics Announces Phase I Trial of DR10624

Wednesday, August 02, 2023

Zhejiang Doer Biologics has announced the successful dosing completion of the initial participant in their Phase Ib 12-week Multiple-Ascending Dose (MAD) trial for DR10624. 

This first-in-class (FIC) compound functions as a tri-specific agonist, targeting Glucagon-like peptide-1 receptor (GLP-1R), Glucagon receptor (GCGR), and Fibroblast growth factor 21 receptor (FGF21R). The study's primary focus is evaluating DR10624's potential for treating obesity and hypertriglyceridemia in New Zealand.

The Phase I MAD (Multiple Ascending Dose) study is a clinical trial to investigate the safety, tolerability, pharmacokinetics (how the drug moves within the body), and pharmacodynamics (how the drug interacts with the body) of DR10624.

DR10624 is a novel FIC tri-specific biotherapeutic designed to selectively activate three distinct receptors: GLP-1R (Glucagon-Like Peptide-1 Receptor), GCGR (Glucagon Receptor), and FGF21R (Fibroblast Growth Factor 21 Receptor). The proprietary MultipleBody® platform technology developed by Doer Bio enables to exhibit balanced activity for metabolic diseases.

In preclinical investigations, DR10624 consistently exhibited favourable outcomes, including reductions in body weight, improved glucose levels, enhanced metabolic function, and better liver functionality.

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinRehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024